Nicotinamide inhibits melanoma in vitro and in vivo.
Dietary intake
HCAR2
HCAR3
Melanoma
Melanoma mouse-animal model
Metabolism
Nicotinamide
Sirtuin 2
Vitamin B3
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
30
07
2020
accepted:
24
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
6
7
2021
Statut:
epublish
Résumé
Even though new therapies are available against melanoma, novel approaches are needed to overcome resistance and high-toxicity issues. In the present study the anti-melanoma activity of Nicotinamide (NAM), the amide form of Niacin, was assessed in vitro and in vivo. Human (A375, SK-MEL-28) and mouse (B16-F10) melanoma cell lines were used for in vitro investigations. Viability, cell-death, cell-cycle distribution, apoptosis, Nicotinamide Adenine Dinucleotide NAM reduced up to 90% melanoma cell number and induced: i) accumulation in G1-phase (40% increase), ii) reduction in S- and G2-phase (about 50% decrease), iii) a 10-fold increase of cell-death and 2.5-fold increase of apoptosis in sub-G1 phase, iv) a significant increase of NAD NAM shows a relevant anti-melanoma activity in vitro and in vivo and is a suitable candidate for further clinical investigations.
Sections du résumé
BACKGROUND
BACKGROUND
Even though new therapies are available against melanoma, novel approaches are needed to overcome resistance and high-toxicity issues. In the present study the anti-melanoma activity of Nicotinamide (NAM), the amide form of Niacin, was assessed in vitro and in vivo.
METHODS
METHODS
Human (A375, SK-MEL-28) and mouse (B16-F10) melanoma cell lines were used for in vitro investigations. Viability, cell-death, cell-cycle distribution, apoptosis, Nicotinamide Adenine Dinucleotide
RESULTS
RESULTS
NAM reduced up to 90% melanoma cell number and induced: i) accumulation in G1-phase (40% increase), ii) reduction in S- and G2-phase (about 50% decrease), iii) a 10-fold increase of cell-death and 2.5-fold increase of apoptosis in sub-G1 phase, iv) a significant increase of NAD
CONCLUSION
CONCLUSIONS
NAM shows a relevant anti-melanoma activity in vitro and in vivo and is a suitable candidate for further clinical investigations.
Identifiants
pubmed: 33028392
doi: 10.1186/s13046-020-01719-3
pii: 10.1186/s13046-020-01719-3
pmc: PMC7542872
doi:
Substances chimiques
Vitamin B Complex
12001-76-2
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Subventions
Organisme : Ministero della Salute
ID : RC-2019 3.4
Références
PLoS One. 2013 Oct 03;8(10):e76731
pubmed: 24098558
Photochem Photobiol Sci. 2020 Feb 19;19(2):171-179
pubmed: 31942903
Photodermatol Photoimmunol Photomed. 2018 Jan;34(1):5-12
pubmed: 28681504
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
Exp Dermatol. 2015 Mar;24(3):209-14
pubmed: 25565012
Cancer Cell. 2011 Oct 18;20(4):487-99
pubmed: 22014574
Biomolecules. 2020 Mar 20;10(3):
pubmed: 32245130
Eur J Cancer. 2014 Jan;50(2):290-301
pubmed: 24183459
Cancer Prev Res (Phila). 2019 Feb;12(2):69-78
pubmed: 30606719
Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):657-61
pubmed: 24071780
Nat Commun. 2015 Feb 12;6:6263
pubmed: 25672491
Int J Tryptophan Res. 2018 May 21;11:1178646918776658
pubmed: 29844677
J Cosmet Dermatol. 2014 Dec;13(4):324-8
pubmed: 25399625
N Engl J Med. 2015 Oct 22;373(17):1618-26
pubmed: 26488693
J Proteomics. 2018 Jan 6;170:99-109
pubmed: 28882678
Exp Dermatol. 2019 Feb;28 Suppl 1:15-22
pubmed: 30698874
Int J Mol Sci. 2019 Nov 26;20(23):
pubmed: 31779194
Oncol Lett. 2019 Aug;18(2):1915-1921
pubmed: 31423261
J Nucleic Acids. 2010 Jul 25;2010:
pubmed: 20725615
Biomolecules. 2020 Apr 29;10(5):
pubmed: 32365524
Cancer Cell Int. 2020 Jan 30;20:36
pubmed: 32021565
Innate Immun. 2015 Nov;21(8):813-26
pubmed: 26385774
Mol Cancer Ther. 2009 Jul;8(7):1878-84
pubmed: 19584232
Diabetologia. 2000 Nov;43(11):1337-45
pubmed: 11126400
Cell Cycle. 2014;13(18):2821-6
pubmed: 25486469
Mol Cancer Res. 2008 May;6(5):760-9
pubmed: 18505921
Mediators Inflamm. 2014;2014:292376
pubmed: 24523569
Cell Biol Int. 2017 Oct;41(10):1127-1145
pubmed: 28755485
Australas J Dermatol. 2014 Aug;55(3):169-75
pubmed: 24635573
J Invest Dermatol. 2019 Feb;139(2):467-469
pubmed: 30244097
Clin Cancer Res. 2005 Oct 15;11(20):7234-42
pubmed: 16243793
Life Sci. 2019 Aug 1;230:121-131
pubmed: 31125565
Eur J Pharmacol. 2017 Feb 15;797:1-8
pubmed: 28088387
Radiother Oncol. 1993 May;27(2):131-9
pubmed: 8356223
Drugs. 2018 Aug;78(12):1197-1209
pubmed: 30097888
J Exp Med. 2003 Feb 3;197(3):387-93
pubmed: 12566422
Tohoku J Exp Med. 2018;244(3):243-248
pubmed: 29563389
Photochem Photobiol. 2010 Jul-Aug;86(4):942-8
pubmed: 20492562
Oncotarget. 2016 Nov 22;7(47):77257-77275
pubmed: 27764787
J Dermatol Sci. 2015 Aug;79(2):155-62
pubmed: 25982144
Semin Cell Dev Biol. 2020 Feb;98:192-201
pubmed: 31059816
Metabolomics. 2019 Oct 5;15(10):137
pubmed: 31587111
Tissue Antigens. 2007 Jul;70(1):1-11
pubmed: 17559575
J Biol Chem. 2012 Jun 1;287(23):19304-14
pubmed: 22493485
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091806
Oncogene. 2011 Dec 15;30(50):4930-40
pubmed: 21643009
Nat Commun. 2016 Oct 12;7:13135
pubmed: 27731314
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Int J Tryptophan Res. 2017 Jun 14;10:1178646917713491
pubmed: 28659716
Cancer Res. 2003 Nov 1;63(21):7436-42
pubmed: 14612543
Immunotherapy. 2017 Jan;9(2):115-121
pubmed: 28128709
PLoS One. 2017 Apr 18;12(4):e0175950
pubmed: 28419143
Front Pharmacol. 2019 Jan 30;10:38
pubmed: 30761005
J Exp Clin Cancer Res. 2018 Dec 28;37(1):326
pubmed: 30591049
Tumour Biol. 2013 Jun;34(3):1847-54
pubmed: 23475622
Eur J Pharmacol. 2015 Sep 5;762:283-92
pubmed: 26048310
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Pathology. 2013 Apr;45(3):331-41
pubmed: 23478234
Cancers (Basel). 2019 Mar 29;11(4):
pubmed: 30934896
Cell Chem Biol. 2017 Mar 16;24(3):339-345
pubmed: 28286128
Metabolism. 2018 May;82:72-87
pubmed: 29330025
Photochem Photobiol Sci. 2010 Apr;9(4):578-85
pubmed: 20354654
J Immunol. 2001 Jun 15;166(12):7370-80
pubmed: 11390488
Cancer Res. 2016 Dec 1;76(23):6864-6876
pubmed: 27634753
Biochem Biophys Res Commun. 2003 Sep 26;309(3):558-66
pubmed: 12963026
Chem Biol Interact. 2015 Jul 5;236:9-18
pubmed: 25912555
Nutr Cancer. 1999;34(1):36-41
pubmed: 10453439
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101
pubmed: 31296229
Alcohol Alcohol. 2014 May-Jun;49(3):238-50
pubmed: 24627570
J Nutr Sci Vitaminol (Tokyo). 2018;64(2):90-98
pubmed: 29710037
J Invest Dermatol. 2014 Jun;134(6):1693-1700
pubmed: 24480879
Biochem Biophys Res Commun. 2010 Apr 30;395(2):281-7
pubmed: 20380810
Biochem Pharmacol. 2019 Apr;162:142-153
pubmed: 30352233
Cancer Res. 2010 Jan 1;70(1):8-11
pubmed: 20028851
Br J Dermatol. 2016 Dec;175(6):1363-1365
pubmed: 27062605
Br J Pharmacol. 2020 May 7;:
pubmed: 32383227
Mol Carcinog. 2019 Oct;58(10):1876-1885
pubmed: 31292999
J Biol Chem. 1965 Apr;240:1725-30
pubmed: 14285515
J Invest Dermatol. 2002 Jun;118(6):915-22
pubmed: 12060384
PLoS One. 2013;8(2):e57160
pubmed: 23451174
J Clin Invest. 1997 Mar 1;99(5):1064-71
pubmed: 9062365
Tumour Biol. 2015 Jun;36(6):4339-48
pubmed: 25596087
J Cosmet Dermatol. 2004 Apr;3(2):88-93
pubmed: 17147561
Int J Mol Sci. 2019 Sep 14;20(18):
pubmed: 31540057
Arch Physiol Biochem. 2019 Dec;125(5):470-477
pubmed: 31291133